Compounds and methods for increasing endogenous levels of corticotropin-releasing factor
US5959109A · kind A · utility
17Cited by
1References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 15, 1996 |
| Grant date | Sep 28, 1999 |
| Priority date | — |
| Expiry date | May 15, 2016 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D487/04
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Ligand inhibitors for increasing levels of free corticotropin-releasing factor (CRF) in the brain. Such ligand inhibitors cause release of CRF from the CRF/CRF-binding protein complex. Administration of the ligand inhibitors provide improvement in learning and memory, result in decreased food intake and/or provide treatment for diseases associated with low levels of CRF in the brain, notably Alzheimer's disease. The ligand inhibitor is represented by the formula: ##STR1##
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.